IGHE and allergic asthma: Omalizumab is a humanized recombinant monoclonal antibody approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) as add-on treatment for patients ≥6 years old with moderate-to-severe persistent allergic asthma and unsatisfactory response to inhaled corticosteroid (ICS), high serum immunoglobulin E (IgE) levels (30–1,500 IU/ml) and positive specific serum IgE to at least one aeroallergen (1–3).